Skip to content

Effects of transcutaneous auricular vagus nerve stimulation on postoperative delirium in elderly patients undergoing laparoscopic radical resection of gastrointestinal malignancies

Effects of transcutaneous auricular vagus nerve stimulation on postoperative delirium in elderly patients undergoing laparoscopic radical resection of gastrointestinal malignancies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127651
Enrollment
Unknown
Registered
2026-07-03
Start date
2026-07-03
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

Experimental group:Active transcutaneous auricular vagus nerve stimulation (active taVNS)
Control group:Sham transcutaneous auricular vagus nerve stimulation (sham taVNS)

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years old; 2. Scheduled for laparoscopic radical resection of gastrointestinal malignancies under general anesthesia; 3. ASA classification: II-III grade; 4. Preoperative MMSE score: illiterate >= 17 points, primary school education >= 20 points, junior high school or above >= 24 points; 5. Voluntary participation and signing of informed consent form.

Exclusion criteria

Exclusion criteria: 1.Abnormal auricular anatomy, or skin damage and infection in the concha; 2.Preoperative delirium; 3.Current or previous neuropsychiatric disorders (e.g., traumatic brain injury, brain tumor, cerebrovascular accident, epilepsy, major depressive disorder, or schizophrenia); 4.History of craniocerebral surgery; 5.Severe cardiovascular diseases (e.g., severe sinus bradycardia or atrioventricular block, NYHA functional class >= 3); 6.Severe respiratory diseases (e.g., respiratory failure); 7.Severe hepatic or renal dysfunctions (e.g., Child–Pugh class C, eGFR < 45 mL / min / 1.73 m^2); 8.Severe visual or hearing impairments, or inability to communicate; 9.Alcohol or substance abuse; 10.Presence of implantable electrical stimulation devices (e.g., cardiac pacemaker); 11.Refusal to participate, or enrollment in another clinical trial;

Design outcomes

Primary

MeasureTime frame
Incidence of delirium within 3 days after surgery;

Secondary

MeasureTime frame
Incidence of delirium within 7 days after surgery;Postoperative hospital stay;Subtypes of delirium;Severity of delirium;Time to first onset and duration of delirium;Pain score;Postoperative inflammatory markers;Postoperative analgesic pump consumption;Incidence of delayed neurocognitive recovery;Sleep quality score;Gastrointestinal function score;Adverse events;Nausea and vomiting score;Anxiety score;Depression score;Fatigue score;Quality of recovery score;Number of postoperative rescue analgesia;Time to first postoperative flatus;Time to first tolerance of oral intake after surgery;Time to first postoperative ambulation;

Countries

China

Contacts

Public ContactJunli Cao

The Affiliated Hospital of Xuzhou Medical University

caojl0310@aliyun.com+86 516 8326 2686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026